ARTV$12.11
$13.26
Chart
Performance
Key Stats
AI ARTV Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldArtiva Biotherapeutics (ARTV) shows potential in the biotech sector with a focus on NK cell therapies, but faces significant financial headwinds and market skepticism. Long-term outlook is uncertain, requiring careful monitoring of clinical trial progress and financial stability.
Thematic
The company operates in the rapidly growing field of cell therapy for autoimmune diseases and cancers, a high-potential area within biotechnology. Advancements in NK cell therapy are a strong thematic tailwind.
Fundamental
Artiva Biotherapeutics exhibits significant financial strain with negative earnings, minimal revenue, and substantial cash burn. While it possesses assets and a balance sheet, its operational viability is heavily reliant on future funding and successful clinical development.
Technical
The stock price has experienced extreme volatility, with a sharp decline over the past year. While current price action shows some upward momentum in the short term, it faces resistance. Technical indicators are mixed, suggesting a neutral short-term outlook.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 85 |
| Oncology & Autoimmune Disease Focus | 80 |
| Advancements in Cell Therapy | 70 |
| Competitive Landscape | 65 |
| Regulatory Pathway for Novel Therapies | 75 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 5 |
| Growth | 10 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 60 |
| Support & Resistance | 50 |
| Volume Confirmation | 60 |
| Short-term Performance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprise
The company has beaten earnings estimates in the last two reported quarters (Q1 2025: +12.58%, Q4 2024: -1.28% compared to estimates). Q1 2025 showed a significant positive surprise, indicating potential operational improvements or better-than-expected market conditions.
Potential Undervaluation
The Price-to-Sales (PS) ratio for 2023 was 2.6 and for 2024 (annualized) is 978.4 (note: likely data anomaly for 2024 PS ratio due to low revenue, but 2023 PS ratio is relatively low). The negative Price-to-Earnings (PE) ratio indicates the company is not currently profitable, which is common for clinical-stage biotech companies.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses, with a net income of -$58.493 million in Q4 2024 and -$27.696 million in Q4 2023. The EPS for 2025 is projected to be negative (-$0.71 for Q2, -$0.75 for Q1).
Negligible Revenue
Reported revenue for Q4 2024 was only $251,000, a significant decrease from $33.492 million in Q4 2023. This indicates a potential issue with commercialization or a shift in business focus.
Calendar
August 2025
7
Next Earnings Date
H: $-0.77
A: $-0.77
L: $-0.77
Profile
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Seasonals
Price Target
15.40 USD
The 39 analysts offering 1 year price forecasts for ARTV have a max estimate of 19.00 and a min estimate of 10.00.